Apnimed, Inc.

APMD

priced

Analyst-verified

Apnimed, Inc. is a late stage clinical pharmaceutical company focused on developing and commercializing novel oral therapies for sleep-related breathing diseases. Their main product candidate, AD109 (Oxnimbi), is designed to treat obstructive sleep apnea by improving upper airway muscle activity.

Offering

View source filing

Exchange: NASDAQ Global Select
Source: Finnhub
Price: $16.00
Source: Finnhub
Shares offered: 12,000,000
Source: Finnhub
Expected date: 2026-07-31
Source: Finnhub
Priced date: 2026-07-31
Source: Finnhub
Industry: Pharmaceuticals
AI-extracted
Revenue: —
Net income: —

Underwriters

Not yet disclosed.

Filings

S-1/A 2026-07-27View on EDGAR
S-1 2026-07-10View on EDGAR

Track APMD

Get alerts on new filings and ask our AI analyst about this company.

Start 3-day trial